Core Insights - Ovid Therapeutics reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, marking an earnings surprise of -13.33% [1] - The company generated revenues of $0.13 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 61.18% and down from $0.17 million a year ago [2] - Ovid Therapeutics shares have increased by approximately 44.6% since the beginning of the year, outperforming the S&P 500's gain of 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $0.24 million, and for the current fiscal year, it is -$0.44 on revenues of $6.82 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Ovid Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ovid Therapeutics' stock performance [5] Future Expectations - The estimate revisions trend for Ovid Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6] - The upcoming earnings call will be crucial for understanding management's commentary on future earnings expectations [3][4]

Group 1 - Twist Bioscience reported a quarterly loss of $0.66 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.56, but an improvement from a loss of $0.79 per share a year ago, indicating an earnings surprise of -17.86% [1] - The company posted revenues of $92.79 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.95% and showing an increase from year-ago revenues of $75.3 million [2] - Over the last four quarters, Twist Bioscience has exceeded consensus revenue estimates four times, indicating a positive trend in revenue performance [2] Group 2 - The stock has underperformed the market, losing about 15.6% since the beginning of the year compared to the S&P 500's decline of -3.3% [3] - The earnings outlook for Twist Bioscience is currently unfavorable, leading to a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.56 on revenues of $94.77 million, and for the current fiscal year, it is -$2.14 on revenues of $374.42 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Twist Bioscience belongs, is currently in the top 34% of Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]